

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6359331/marco-ladetto-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

284 papers	8,528 citations	53 h-index	88 g-index
292 ext. papers	9,860 ext. citations	3.7 avg, IF	5.32 L-index

#	Paper	IF	Citations
284	MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 12885-90	11.5	467
283	Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015 , 26 Suppl 5, v116-25	10.3	397
282	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2013 , 24, 857-77	10.3	225
281	Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2077-84	2.2	223
280	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020 , 7, e737-e745	14.6	223
279	Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. <i>Leukemia</i> , 2014 , 28, 1299-307	10.7	213
278	Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008 , 111, 4004-13	2.2	200
277	Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. <i>Journal of Clinical Oncology</i> , 1999 , 17, 208-15	2.2	198
276	Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. <i>Blood</i> , 2012 , 119, 2066-73	2.2	186
275	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013 , 24, 561-76	10.3	162
274	Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. <i>Clinical Cancer Research</i> , 2009 , 15, 4415-22	12.9	155
273	Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. <i>Nature Medicine</i> , 2000 , 6, 667-72	50.5	155
272	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , 2013 , 122, 2673-82	2.2	154
271	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016 , 27, v83-v90	10.3	142
270	Molecular Monitoring of Minimal Residual Disease in Follicular and Mantle Cell Non-Hodgkin's Lymphomas Treated With High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Autografting. <i>Blood</i> , 1997 , 89, 724-491	2.2	142
269	Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv19-iv29	10.3	142
268	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , 2014 , 15, 730-7	21.7	135

267	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017 , 28, iv62-iv71	10.3	134
266	Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. <i>Blood</i> , 2002 , 99, 75-82	2.2	133
265	Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013 , 24 Suppl 6, vi144-8	10.3	132
264	MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. <i>Blood</i> , 2007 , 110, 3744-52	2.2	132
263	Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii70-5	10.3	127
262	Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. <i>Blood</i> , 2000 , 95, 2651-2658	2.2	120
261	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014 , 25, 1404-1410	10.3	114
260	Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1460-8	2.2	113
259	Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015 , 26 Suppl 5, v108-15	10.3	107
258	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii83-92	10.3	104
257	The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. <i>Blood</i> , 2007 , 110, 4464-75	2.2	104
256	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv30-iv40	10.3	99
255	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013 , 24 Suppl 6, vi149-54	10.3	98
254	A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. <i>Leukemia</i> , 1997 , 11, 1793-8	10.7	94
253	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 652-60	5.1	92
252	AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. <i>Oncogene</i> , 2010 , 29, 2325-36	9.2	90
251	Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009 , 23, 1062-72	10.7	85
250	Epigenomic evolution in diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2015 , 6, 6921	17.4	81

249	High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2002 , 100, 1559-65	2.2	80
248	Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020 , 31, 17-29	10.3	77
247	Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 241-53	4.7	76
246	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , 2017 , 4, e15-e23	14.6	75
245	Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. <i>Blood</i> , 2005 , 105, 4784-91	2.2	74
244	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 552-560	2.2	69
243	Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. <i>Clinical Cancer Research</i> , 2014 , 20, 6398-405	12.9	69
242	Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016 , 27, v91-v102	10.3	69
241	Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. <i>Leukemia</i> , 2015 , 29, 689-95	10.7	68
240	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii76-82	10.3	67
239	CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. <i>Haematologica</i> , 2008 , 93, 1575-9	6.6	66
238	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013 , 122, 3759-66	2.2	63
237	MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1087-90	1.9	57
236	13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 633-43	5	57
235	A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. <i>Experimental Hematology</i> , 2001 , 29, 183-93	3.1	57
234	Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). <i>Leukemia</i> , 2007 , 21, 1802-11	10.7	55
233	Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. <i>Blood</i> , 2016 , 127, 858-68	2.2	54
232	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. <i>Leukemia</i> , 2011 , 25, 828-37	10.7	53

231	mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , 2020 , 105, 1604-1612	6.6	52
230	Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. <i>Leukemia</i> , 2012 , 26, 1081-90	10.7	50
229	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4015-4022	2.2	49
228	Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3351-8	2.2	48
227	Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2013 , 98, 1732-8	6.6	48
226	Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1270-6	4.7	47
225	The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. <i>American Journal of Hematology</i> , 2013 , 88, 1062-7	7.1	44
224	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018 , 29, 544-562	10.3	42
223	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. <i>Leukemia</i> , 2001 , 15, 1941-9	10.7	42
222	Dysfunctional V β V α T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012 , 120, 3271-9	2.2	40
221	Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2007 , 21, 697-705	10.7	40
220	Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. <i>Blood</i> , 2004 , 103, 4644-9	2.2	39
219	Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies. <i>Leukemia</i> , 1999 , 13, 1691-5	10.7	37
218	Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011 , 154, 590-9	4.5	35
217	Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. <i>Leukemia</i> , 1999 , 13, 1456-62	10.7	35
216	High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. <i>Haematologica</i> , 2014 , 99, e14-6	6.6	33
215	Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. <i>Hematological Oncology</i> , 2011 , 29, 167-76	1.3	33
214	ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. <i>Frontiers in Oncology</i> , 2012 , 2, 41	5.3	33

213	PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1398-403	2.2	33
212	Highly sensitive mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. <i>Haematologica</i> , 2018 , 103, 1029-1037	6.6	32
211	Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. <i>Leukemia</i> , 2000 , 14, 740-7	10.7	31
210	Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2016 , 30, 1211-4	10.7	30
209	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 783-91	4	30
208	The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2011 , 117, 2405-13	2.2	28
207	Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF. <i>Leukemia</i> , 2005 , 19, 644-51	10.7	26
206	Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. <i>British Journal of Haematology</i> , 1996 , 94, 376-8	4.5	26
205	Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir. <i>Experimental Hematology</i> , 2007 , 35, 673-81	3.1	25
204	Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. <i>Medical Oncology</i> , 2000 , 17, 203-10	3.7	25
203	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. <i>Oncotarget</i> , 2015 , 6, 29833-46	3.3	25
202	High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. <i>Leukemia</i> , 2001 , 15, 256-63	10.7	23
201	N- and K-ras oncogenes in plasma cell dyscrasias. <i>Leukemia and Lymphoma</i> , 1994 , 15, 17-20	1.9	23
200	Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. <i>Experimental Hematology</i> , 2002 , 30, 529-36	3.1	22
199	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL). <i>Thrombosis and Haemostasis</i> , 2017 , 117,	7	19
198	Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network. <i>HemaSphere</i> , 2020 , 4, e347	0.3	19
197	MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. <i>British Journal of Haematology</i> , 2014 , 164, 841-50	4.5	18
196	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. <i>Hematological Oncology</i> , 2012 , 30, 46-9	1.3	18

195	Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2017 , 102, e203-e206	6.6	17
194	Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1372-1378	4.7	17
193	Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. <i>Leukemia</i> , 2006 , 20, 1840-7	10.7	17
192	Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016 , 128, 176-176	2.2	17
191	BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. <i>Leukemia</i> , 2003 , 17, 2238-40	10.7	15
190	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021 , 195, 371-377	4.5	15
189	Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3. <i>Cancer</i> , 2003 , 98, 983-92	6.4	14
188	Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. <i>Annals of Hematology</i> , 2013 , 92, 1503-11	3	13
187	Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. <i>Annals of Oncology</i> , 2013 , 24, 1378-84	10.3	13
186	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , 2018 , 103, 849-856	6.6	12
185	Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders. <i>Methods in Molecular Biology</i> , 2018 , 1768, 229-256	1.4	12
184	Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2013 , 4, 189-98	5.7	12
183	Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. <i>Bone Marrow Transplantation</i> , 2010 , 45, 505-12	4.4	12
182	Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. <i>Experimental Hematology</i> , 2003 , 31, 784-8	3.1	12
181	Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations. <i>Experimental Hematology</i> , 2006 , 34, 1680-6	3.1	11
180	Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance. <i>Hematological Oncology</i> , 2014 , 32, 133-8	1.3	10
179	Telomeres and telomerase in normal and malignant B-cells. <i>Hematological Oncology</i> , 2010 , 28, 157-67	1.3	10
178	Cytomegalovirus infection in cancer patients receiving granulocyte transfusions. <i>Blood</i> , 2002 , 99, 390-1	2.2	10

177	Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study. <i>Blood</i> , 2008 , 112, 3683-3683	2.2	10
176	Controversies in the Treatment of Follicular Lymphoma. <i>HemaSphere</i> , 2020 , 4, e317	0.3	9
175	A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1664-1670	4.7	9
174	Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma. <i>Blood Cancer Journal</i> , 2014 , 4, e249	7	9
173	Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. <i>Mechanisms of Ageing and Development</i> , 2012 , 133, 479-88	5.6	9
172	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. <i>Haematologica</i> , 2012 , 97, 849-53	6.6	9
171	Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome. <i>American Journal of Hematology</i> , 2010 , 85, 619-22	7.1	9
170	Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. <i>British Journal of Haematology</i> , 2002 , 117, 642-5	4.5	9
169	A Molecular Model for the Prediction of Progression Free Survival in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation: Results from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015 , 126, 336-336	2.2	9
168	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021 , 8, e34-e44	14.6	9
167	Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. <i>American Journal of Hematology</i> , 2015 , 90, 230-4	7.1	8
166	Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients.. <i>Blood</i> , 2007 , 110, 530-530	2.2	8
165	Incidence and outcome of Kaposi sarcoma after hematopoietic stem cell transplantation: a retrospective analysis and a review of the literature, on behalf of infectious diseases working party of EBMT. <i>Bone Marrow Transplantation</i> , 2020 , 55, 110-116	4.4	8
164	HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data. <i>BMC Bioinformatics</i> , 2017 , 18, 516	3.6	7
163	Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. <i>Hematological Oncology</i> , 2019 , 37, 368-374	1.3	7
162	Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003 , 32, 791-3	4.4	7
161	Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma. <i>Methods in Molecular Medicine</i> , 2005 , 113, 145-63		7
160	Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification. <i>Blood</i> , 2018 , 132, 920-920	2.2	7

159	Triangle: Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a Randomized European MCL Network Trial. <i>Blood</i> , 2019 , 134, 2816-2816 ^{2,3}	7
158	Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP.. <i>Blood</i> , 2009 , 114, 99-99	2.2 7
157	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101234	2.2 7
156	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-III trial. <i>Haematologica</i> , 2019 , 104, 2241-2248	6.6 6
155	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting). <i>Leukemia and Lymphoma</i> , 2016 , 57, 1256-68	1.9 6
154	Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting. <i>Leukemia and Lymphoma</i> , 2001 , 40, 679-82	1.9 6
153	Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis. <i>International Journal of Laboratory Hematology</i> , 2018 , 40, 201-208	2.5 6
152	Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2018 , 132, 401-401	2.2 6
151	LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL. <i>Blood</i> , 2011 , 118, 827-827	2.2 6
150	Data quality improvement of a multicenter clinical trial dataset. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , 2017 , 2017, 1190-1193	0.9 5
149	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2904-2910	1.9 5
148	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2019 , 60, 2890-2898	1.9 5
147	Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. <i>Bone Marrow Transplantation</i> , 1997 , 20, 341-3	4.4 5
146	Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi. <i>Blood</i> , 2019 , 134, 398-398	2.2 5
145	A Comparative Analysis Of Next-Generation Sequencing and Real-Time Quantitative PCR For Minimal Residual Disease Detection In Follicular Lymphomas. <i>Blood</i> , 2013 , 122, 4293-4293	2.2 5
144	Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes. <i>JCO Clinical Cancer Informatics</i> , 2019 , 3, 1-15	5.2 5
143	A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. <i>Future Oncology</i> , 2021 , 17, 255-262	3.6 5
142	Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 71	5.4 5

141	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. <i>Cancers</i> , 2021 , 13,	6.6	5
140	Home management of hematological patients requiring hospital admission. <i>Archives of Gerontology and Geriatrics</i> , 2010 , 51, 309-11	4	4
139	High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission. <i>Medical Oncology</i> , 2006 , 23, 359-68	3.7	4
138	EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy. <i>Blood</i> , 2019 , 134, 124-124	2.2	4
137	AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3 β <i>Blood</i> , 2008 , 112, 251-251	2.2	4
136	Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL). <i>Stem Cells</i> , 2011 , 118, 177-177	2.2	4
135	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2021 ,	7.8	4
134	Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. <i>Hematological Oncology</i> , 2021 , 39, 293-303	1.3	4
133	Droplet Digital PCR Assay for : Clinical Applications in Waldenström Macroglobulinemia. <i>HemaSphere</i> , 2020 , 4, e324	0.3	3
132	Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network. <i>Leukemia and Lymphoma</i> , 2016 , 57, 400-410	1.0	3
131	Methods and role of minimal residual disease after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019 , 54, 681-690	4.4	3
130	The mutation of N-ras oncogene does not involve myeloid and erythroid lineages in a case of multiple myeloma. <i>British Journal of Haematology</i> , 1993 , 83, 672-3	4.5	3
129	Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIP1 2B) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis.. <i>Blood</i> , 2004 , 104, 891-891	2.2	3
128	Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial.. <i>Blood</i> , 2005 , 106, 675-675	2.2	3
127	The Outcome of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP (R-CHOP) Is Not Predicted by 18-FDG-Positron Emission Tomography/Computerized Tomography (PET) Performed at Intermediate In-Course Evaluation, but Only by PET Assessed at the End of Therapy.. <i>Blood</i> , 2010 , 116, 2819-2819	2.2	3
126	Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial. <i>Blood</i> , 2013 , 122, 551-551	2.2	3
125	Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi. <i>Blood</i> , 2013 , 122, 850-850	2.2	3
124	Prognostic Impact of p190 and p210 Co-Expression at Diagnosis in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib. <i>Blood</i> , 2014 , 124, 5528-5528	2.2	3

123	Distinct Immunogenetic Signatures in IgA Versus IgG Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2062-2062	2.2	3
122	Organizational determinants of hospital stay: establishing the basis of a widespread action on more efficient pathways in medical units. <i>Internal and Emergency Medicine</i> , 2020 , 15, 1011-1019	3.7	3
121	Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance. <i>Hematology/Oncology Clinics of North America</i> , 2020 , 34, 887-901	3.1	3
120	A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021 , 193, 280-289	4.5	3
119	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. <i>Haematologica</i> , 2019 , 104, e410-e414	6.6	2
118	Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study. <i>Blood</i> , 2020 , 136, 21-22	2.2	2
117	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018 , 132, 922-922 ^{2,2}	2.2	2
116	Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.. <i>Blood</i> , 2004 , 104, 1320-1320	2.2	2
115	Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS.. <i>Blood</i> , 2006 , 108, 325-325	2.2	2
114	Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.. <i>Blood</i> , 2009 , 114, 960-960	2.2	2
113	Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL). <i>Blood</i> , 2012 , 120, 746-746	2.2	2
112	Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012 , 120, 903-903	2.2	2
111	Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi. <i>Blood</i> , 2013 , 122, 3047-3047	2.2	2
110	The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP. <i>Blood</i> , 2014 , 124, 2964-2964	2.2	2
109	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. <i>Blood</i> , 2016 , 128, 1102-1102	2.2	2
108	Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi. <i>Blood</i> , 2016 , 128, 472-472	2.2	2
107	Minimal Residual Disease in Multiple Myeloma. <i>Hematologic Malignancies</i> , 2018 , 97-109	0	1
106	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. <i>British Journal of Haematology</i> , 2018 , 181, 693-695	4.5	1

105	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naïve patients.. <i>Blood Cancer Journal</i> , 2022 , 12, 8	7	1
104	Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2019 , 134, 698-698	2.2	1
103	Telomerase Inhibitor BIBR1532 Induces Telomere Shortening and Growth Inhibition in Extra-Germinal Center (GC)-Derived Lymphoid Cell Lines.. <i>Blood</i> , 2004 , 104, 3389-3389	2.2	1
102	Qualitative and Quantitative Molecular Follow up of Minimal Residual Disease after Non Myeloablative Allografting for Multiple Myeloma.. <i>Blood</i> , 2004 , 104, 5128-5128	2.2	1
101	High CR Rate and Prolonged EFS in aaIPI 2 B Diffuse Large B-Cell Lymphoma Following High-Dose Sequential Chemotherapy and In Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen): Results of a Prospective Phase II Multicenter Study Sponsored by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).. <i>Blood</i> , 2005 , 106, 2068-2068	2.2	1
100	Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638). <i>Blood</i> , 2007 , 110, 1278-1278	2.2	1
99	The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007 , 110, 1672-1672	2.2	1
98	Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (FL): Updated Results Suggest the Use of R-HDS as Salvage Treatment.. <i>Blood</i> , 2007 , 110, 20-20	2.2	1
97	Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial. <i>Blood</i> , 2008 , 112, 834-834	2.2	1
96	Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.. <i>Blood</i> , 2008 , 112, 1786-1786	2.2	1
95	A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?.. <i>Blood</i> , 2009 , 114, 882-882	2.2	1
94	SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. <i>Blood</i> , 2010 , 116, 3611-3611	2.2	1
93	Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL).. <i>Blood</i> , 2012 , 120, 2720-2720	2.2	1
92	Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM). <i>Blood</i> , 2012 , 120, 768-768	2.2	1
91	Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM. <i>Blood</i> , 2013 , 122, 4290-4290	2.2	1
90	Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial. <i>Blood</i> , 2013 , 122, 4384-4384	2.2	1
89	Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014 , 124, 44-44	2.2	1
88	Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms. <i>Blood</i> , 2015 , 126, 1411-1411 ¹	2.2	1

87	Prognostic Impact of p190 and p210 Co-Expression in Early Molecular Response in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosin Kinase Inibitors. <i>Blood</i> , 2016 , 128, 5446-5446	2.2	1
86	Graft Purity and Composition Significantly Impact the Engraftment of Autologous Stem Cell Transplants. <i>Blood</i> , 2016 , 128, 5733-5733	2.2	1
85	Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2021 , 138, 2427-2427	2.2	1
84	Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021 , 138, 811-811	2.2	1
83	p29ING4 Regulates the Production of Pro-Angiogenic Molecules by Human Myeloma Cells in Normoxic and Hypoxic Conditions Being Involved in Myeloma-Induced Angiogenesis.. <i>Blood</i> , 2006 , 108, 515-515	2.2	1
82	Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy. <i>Blood</i> , 2010 , 116, 1784-1784	2.2	1
81	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. <i>Blood</i> , 2013 , 122, 3126-3126	2.2	1
80	Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma. <i>Hematological Oncology</i> , 2020 , 38, 698-704	1.3	1
79	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1944-1952	4.4	1
78	Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2020 , 11, 613954	8.4	1
77	STABLE: a novel approach to de novo assembly of RNA-seq data and its application in a metabolic model network based metatranscriptomic workflow. <i>BMC Bioinformatics</i> , 2018 , 19, 184	3.6	1
76	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2606-2609	4.4	1
75	A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial.. <i>Cancers</i> , 2021 , 14,	6.6	1
74	Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2020 , 136, 16-17	2.2	0
73	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. <i>Blood Advances</i> , 2021 , 5, 1737-1745	7.8	0
72	Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial. <i>British Journal of Haematology</i> , 2021 , 194, 378-381	4.5	0
71	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 481-491	4.4	0
70	Spontaneous splenic rupture during induction therapy in acute myeloid leukemia: An unusual case. <i>Radiology Case Reports</i> , 2021 , 16, 3406-3409	1	0

69	The adulthood of MRD detection in MCL. <i>Blood</i> , 2010 , 115, 3180-1	2.2
68	Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the CmwP EBMT. <i>Blood</i> , 2020 , 136, 26-27	2.2
67	A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial. <i>Blood</i> , 2021 , 138, 41-41	2.2
66	Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome.. <i>Blood</i> , 2004 , 104, 2450-2450	2.2
65	Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo).. <i>Blood</i> , 2004 , 104, 903-903	2.2
64	Telomere Length of Hematopoietic Cells in Long-Term Post-Autograft Survivors: No Evidence of Accelerated Replicative Cell Senescence Despite the Persistent Reduction of Both Committed and Immature Progenitor Cell Compartments.. <i>Blood</i> , 2004 , 104, 4123-4123	2.2
63	Long-Term Monitoring of Cancer-Free Subjects Carrying Non-Lymphoma Associated bcl2/IgH Rearrangements (NLABR): Prolonged Persistence of Clonal Populations Potentially Related to Follicular Lymphoma (FL).. <i>Blood</i> , 2004 , 104, 1373-1373	2.2
62	Telomere Length Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2004 , 104, 4768-4768	2.2
61	Incidence and Risk-Factors of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Chemotherapy and Autograft: A Long-Term Analysis on 307 Lymphoma Patients.. <i>Blood</i> , 2004 , 104, 2248-2248	2.2
60	High Prevalence of Hyperhomocysteine in Retinal Vein Occlusion.. <i>Blood</i> , 2005 , 106, 1617-1617	2.2
59	Telomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients.. <i>Blood</i> , 2005 , 106, 2104-2104	2.2
58	Array-Based Comparative Genomic Hybridization (Array-CGH) in Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL): Recurrent Imbalances within a Highly Heterogeneous Background of Genomic Disruption.. <i>Blood</i> , 2005 , 106, 5088-5088	2.2
57	MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.. <i>Blood</i> , 2006 , 108, 1636-1636	2.2
56	Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR.. <i>Blood</i> , 2006 , 108, 3166-3166	2.2
55	Suspension of Vitamin K Antagonists Is Not Required for Cataract Surgery: A Prospective Study in a Cohort of 135 Consecutive Patients on Long-Term Anticoagulant Therapy.. <i>Blood</i> , 2006 , 108, 882-882	2.2
54	Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2.. <i>Blood</i> , 2006 , 108, 3413-3413	2.2
53	Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis?.. <i>Blood</i> , 2007 , 110, 3025-3025	2.2
52	Non-Hodgkin's Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients.. <i>Blood</i> , 2007 , 110, 1373-1373	2.2

- 51 Phenotypic and Functional Features of V β /V δ T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells.. *Blood*, **2007**, 110, 1131-1131 2.2
- 50 The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. *Blood*, **2018**, 132, 2890-2890 2.2
- 49 A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group. *Blood*, **2019**, 134, 2812-2812 2.2
- 48 Oncogenes in the Pathogenesis of Multiple Myeloma **1996**, 169-172
- 47 Long-term results of the phase III GITMO/FIL trial of CHOP-R versus R-HDS plus autograft in high-risk follicular lymphoma (FL) at diagnosis.. *Journal of Clinical Oncology*, **2014**, 32, 8531-8531 2.2
- 46 Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplant after Brentuximab Vedotin in Patients with Hodgkin Lymphoma Relapsed after Autologous Transplant. *Blood*, **2014**, 124, 5943-5943 2.2
- 45 Highly Sensitive Droplet Digital PCR for MYD88L265P Mutation Detection and Minimal Residual Disease Monitoring in Waldenström Macroglobulinemia. *Blood*, **2015**, 126, 2645-2645 2.2
- 44 Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. *Blood*, **2015**, 126, 3937-3937 2.2
- 43 The Prognostic Role of Cell of Origin Profile and Myc Expression Assessed By Immunohistochemistry in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of First-Line Randomized BIO-DLCL04 Trial of Fondazione Italiana Linfomi (FIL). *Blood*, **2015**, 126, 5041-5041 2.2
- 42 Khorana Score and Histotype Predict the Incidence of Early Venous Thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). a Pooled Data Analysis of Twelve Clinical Trials of Fondazione Italiana Linfomi (FIL). *Blood*, **2015**, 126, 3934-3934 2.2
- 41 LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL). *Blood*, **2015**, 126, 3985-3985 2.2
- 40 Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway. *Blood*, **2015**, 126, 701-701 2.2
- 39 "Osteonecrosis of Jaw (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma (MM) : Monocentric Experience of Decreasing ONJ Incidence after Preventive Measures.". *Blood*, **2016**, 128, 5917-5917 2.2
- 38 Identification of DNA Copy Number Variations Associated with the Clinical Outcome in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in the Prospective from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL). *Blood*, **2016**, 128, 4898-4898 2.2
- 37 Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter Syndrome Transformation in Chronic Lymphocytic Leukemia.. *Blood*, **2008**, 112, 1052-1052 2.2
- 36 Hospital at Home Treatment of Haematological Patients. *Blood*, **2008**, 112, 4686-4686 2.2
- 35 Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. *Blood*, **2008**, 112, 778-778 2.2
- 34 Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia. *Blood*, **2008**, 112, 3183-3183 2.2

- 33 Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.. *Blood*, **2009**, 114, 2928-2928 2.2
- 32 Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.. *Blood*, **2009**, 114, 2333-2333 2.2
- 31 Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents.. *Blood*, **2009**, 114, 1821-1821 2.2
- 30 Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities.. *Blood*, **2009**, 114, 2164-2164 2.2
- 29 Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases.. *Blood*, **2009**, 114, 2808-2808 2.2
- 28 High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study.. *Blood*, **2009**, 114, 1838-1838 2.2
- 27 High Resolution Array-CGH Provides New Insights Into the Prognosis of Chronic Lymphocytic Leukemia (CLL): Is 8p Loss Worse Than 17p Loss?.. *Blood*, **2009**, 114, 2339-2339 2.2
- 26 Identification of New Recurrent Multiple Small Interstitial Deletions Affecting Genes Coding for Kinases in Chronic Lymphocytic Leukemia (CLL): a New Pathogenic Mechanism?.. *Blood*, **2009**, 114, 672-672 2.2
- 25 13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. *Blood*, **2010**, 116, 3578-3578 2.2
- 24 Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL). *Blood*, **2010**, 116, 917-917 2.2
- 23 The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study. *Blood*, **2010**, 116, 992-992 2.2
- 22 High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease. *Blood*, **2010**, 116, 1898-1898 2.2
- 21 The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. *Blood*, **2010**, 116, 3602-3602 2.2
- 20 IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. *Blood*, **2010**, 116, 2951-2951 2.2
- 19 IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals. *Blood*, **2010**, 116, 2431-2431 2.2
- 18 Prospective, Multicenter Phase III Pilot Trial to Evaluate Efficacy and Safety of Lenalidomide Plus Rituximab-CHOP21 (LR-CHOP21) for Elderly Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis of the Intergruppo Italiano Linfomi (IIL) REAL07 Study. *Blood*, **2010**, 116, 2871-2871 2.2
- 17 Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.. *Blood*, **2010**, 116, 3375-3375 2.2
- 16 Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome. *Blood*, **2011**, 118, 2845-2845 2.2

15	The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011 , 118, 735-735	2.2
14	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). <i>Blood</i> , 2011 , 118, 263-263	
13	PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012 , 120, 787-787	2.2
12	Large Genomic Aberrations Are Independent Prognosticators of A Shorter Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia (CLL) Patients with A Normal FISH. <i>Blood</i> , 2012 , 120, 3906-3906	2.2
11	The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012 , 120, 3881-3881	2.2
10	Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA). <i>Blood</i> , 2012 , 120, 3878-3878	2.2
9	The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab. <i>Blood</i> , 2012 , 120, 1553-1553	2.2
8	Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012 , 120, 3653-3653	2.2
7	High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma. <i>Blood</i> , 2012 , 120, 4204-4204	2.2
6	Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors. <i>Blood</i> , 2013 , 122, 2077-2077	2.2
5	Next-Generation Sequencing and Real-Time Quantitative PCR For Quantification Of Low-Level Minimal Residual Disease In Acute Lymphoblastic Leukemia Of Adults. <i>Blood</i> , 2013 , 122, 351-351	2.2
4	Relapsed Or Refractory Aggressive Non Hodgkin B-Cell Lymphomas Treated With Lenalidomide With/Without Rituximab Or Steroids: A Single Center Restrospective Study. <i>Blood</i> , 2013 , 122, 5119-5119 ^{2.2}	
3	Minimal Residual Disease (MRD) in Indolent Lymphomas. <i>Hematologic Malignancies</i> , 2021 , 21-39	0
2	Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network. <i>HemaSphere</i> , 2021 , 5, e639	0.3
1	The role of autologous haematopoietic stem-cell transplantation in mantle cell lymphoma. <i>Lancet Haematology</i> , 2021 , 8, e617-e619	14.6